UC San Diego researchers used teleoperated humanoid robots to complete two preclinical surgeries, including a robot-assisted gallbladder removal.

Texas Biomed signed a Cooperative Research and Development Agreement with the Defense Department to accelerate vaccines, antivirals, diagnostics and other countermeasures.

Gov. Abbott announced a $33.6M TSIF grant to Texas Instruments for upgrades at the Richardson 300mm wafer fab. The project is expected to total about $700M in capital investment.

Wolfspeed sued Navitas and three affiliates in Delaware court, alleging infringement of multiple GaN and SiC patents used in EV and power‑conversion gear.

Caltech dedicated the Dr. Allen and Charlotte Ginsburg Center, a 70,000‑sq‑ft facility with below‑grade labs and collaboration space to advance quantum sensing and gravitational‑wave research.

San Francisco tech employers are using AI chatbots to screen white‑collar candidates — a Greenhouse survey finds the practice is widespread but opaque. Employers say bots widen the funnel; candidates demand disclosure.

Sumit Rana, president of Epic Systems, will step away effective Aug. 14, saying family responsibilities after his father’s death require his attention. Epic named senior R&D leaders to cover his duties.

NewYork‑Presbyterian and Catholic Health are partnering to bring Herbert Irving clinical trials to Long Island patients, with 20 studies already available.

Meta's Muse Image rollout lets public Instagram photos be used to generate AI images unless you opt out. Here’s the quick path to flip the setting.

Illinois launched a $3M X‑Labs Fast Fund to entice NSF quantum teams to build in Chicago, pairing state cash with partner lab access at the new IQMP campus.

Bank of America quietly provided OpenAI a $520M credit line as the company prepares for a potential IPO, a move that underscores Wall Street’s rush for AI listings.

A germline‑targeting HIV vaccine produced broadly neutralizing antibodies in about 44% of vaccinated primates, researchers report. The Nature study is a proof‑of‑principle but not proof of protection.

St. Jude is recruiting Memphis volunteers for a Phase 3 trial testing a once‑monthly HIV prevention pill; eligibility opens at age 16. The EXPrESSIVE‑11 study compares monthly MK‑8527 with daily PrEP.